Use of Botulinum Toxin to Treat Psoriasis
Psoriasis vulgaris is a chronic disease in which psoriatic plaques may appear on the knees, elbows, scalp and trunk. Evidence suggests the role of neurogenic inflammation in the pathogenesis of psoriasis. Botulinum toxin has been shown to have an effect on inhibiting neurogenic inflammation.
Recently, it was reported that patients who suffered from dystonia and had concomitant psoriasis, when treated with botulinum toxin for dystonia noted a dramatic improvement of their psoriatic lesions.
This pilot study will determine the safety and efficacy of botulinum toxin in the management of psoriasis vulgaris.
|Psoriasis Vulgaris||Biological: injection of botulinum toxin type A.||Phase 1|
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Pilot Study on the Safety and Efficacy of Botulinum Toxin Injections in the Treatment of Psoriasis Vulgaris.|
- psoriasis scoring scale [ Time Frame: baseline and 3months ]
- 3mm skin biopsy. [ Time Frame: baseline and at 3 months. ]
|Study Start Date:||January 2009|
|Study Completion Date:||December 2015|
|Primary Completion Date:||June 2015 (Final data collection date for primary outcome measure)|
Experimental: botulinum toxin
injection of botulinum toxin type A
Biological: injection of botulinum toxin type A.
35 to 100 units injected around a skin lesion (plaque) one time.
Other Name: Botox.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00816517
|United States, Minnesota|
|Univerisity of Minnesota|
|Minneapolis, Minnesota, United States, 55444|
|Principal Investigator:||Maria K Hordinsky, MD||University of Minnesota - Clinical and Translational Science Institute|